EQL Pharma AB
The answer first
Does EQL Pharma beat the market?
No, EQL Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 10% of Nordic stocks
- Quality20
- Value35
- Trend27
No. 161 of 195 in healthcare
Max for seven days
Follow EQL Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about EQL Pharma
Your first answer is free, no account needed.
Do you own EQL Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with EQL Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- EQL Pharma has fallen 55.7% over the past year, including dividends.
- Overall, EQL Pharma ranks better than 10% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.4%. The price is 77.8% below its peak now.
What do analysts think of EQL Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 10% of Nordic stocks.
No. 161 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 171 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity1.33
- Asset turnoverSales divided by everything the company owns0.62
- Return on equityProfit divided by equity+0.4%
- Cash conversionOperating cash flow divided by profit22.67
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 64 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity2.7
- P/SPrice divided by sales1.4
- P/EPrice divided by earnings638.9
- P/CFPrice divided by operating cash flow28.2
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 108 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−3.2%
- 6 months−7.3%
- 9 months−62.6%
- 12 months−55.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own EQL Pharma
4 funds we follow own EQL Pharma. The share is how much of the fund the stock makes up.
- Sweden4
From the funds' latest known holdings.
About EQL Pharma
EQL Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 65 employees.
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.


See the full analysis of EQL Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card